Hongene Biotech Corporation, an expert in nucleic acid manufacturing, and ReciBioPharm, an advanced therapeutics CDMO services provider, have announced a strategic collaboration that aims to enhance gene editing drug manufacturing capabilities.
 
The strategic alliance between the two companies creates a unique solution for innovators in the gene editing field. ReciBioPharm will expand its service portfolio to include sgRNA manufacturing, utilizing Hongene’s innovative synthesis process, providing plasmid, mRNA, sgRNA, LNP, and fill-finish services in a single facility. This will streamline the entire development and manufacturing process, mitigating the logistical complexities of dealing with multiple CDMOs, and ultimately accelerating the path for drug development.
 
Vikas Gupta, President of ReciBioPharm, stated, “Our collaboration with Hongene Biotech marks an important step forward for ReciBioPharm, enabling us to offer comprehensive, seamless solutions in the rapidly evolving gene editing sector. The combination of Hongene’s high-quality raw materials and synthesis methods with our capabilities will provide our clients with an unmatched portfolio of services in this developing field.”
 
Wei Jiang, CEO at Hongene Biotech, shared, “Our partnership with ReciBioPharm is set to redefine the manufacturing space for gene editing. Our cutting-edge sgRNA synthesis technology, combined with ReciBioPharm’s expertise in end-to-end mRNA and drug product manufacture, promises to bring a unique solution that has significant value to the healthcare field.”